APLS Apellis Pharmaceuticals

Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week

Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week
EN
09/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc: 1 director

A director at Apellis Pharmaceuticals Inc sold 31,092 shares at 22.950USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

Wedbush Research
  • Wedbush Research
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
 PRESS RELEASE

Apellis Pharmaceuticals to Participate in Upcoming Investor Conference...

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Wells Fargo Healthcare Conference Date/Time: Wednesday, September 3, 2025 at 8:45 a.m. ET Cantor Global Healthcare Conference Date/Time: Thursday, September 4, 2025 at 8:35 a.m. ET Baird Global Healthcare ConferenceDate/Time: Tuesday, September 9, 2025 at 10:15 a.m. ET The live conference webcasts will be pos...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch